Cellular Microvesicles in the Blood of Patients with Systemic Lupus Erythematosus
- 38 Downloads
Systemic lupus erythematosus (SLE) is an autoimmune disease with a complex and largely unclear pathogenesis. Cellular phospholipid microvesicles released upon activation and/or death of a cell have been proposed to play a role in inflammatory autoimmune pathologies, including SLE. Here, circulating microvesicles of various cellular origins were marked with fluorescently labeled cell-specific antibodies and enumerated by flow cytometry in platelet-free plasma obtained from the heparinized blood of 29 SLE patients and 19 normal subjects. Significantly higher concentrations of endothelial-, monocyte-, and erythrocyte-derived microvesicles were found in the SLE patients compared to normal subjects with prevalence of microvesicles originating from endothelial cells. No significant difference was found for platelet-derived microvesicles. A correlation analysis of microvesicle counts with laboratory parameters and clinical features of SLE suggest differential implications of various cell-derived microvesicles in the pathogenesis of SLE. These data suggest that SLE is associated with functional alterations of endotheliocytes, monocytes, and erythrocytes followed by enhanced release of microvesicles that may contribute to inflammation and hypercoagulability.
KeywordsMicrovesicles Systemic lupus erythematosus Flow cytometry
This work was supported by the Program for Competitive Growth at Kazan Federal University. The authors thank T. B. Sibgatullin (Hospital of the Kazan Federal University) and A. N. Maksudova (Republican Clinical Hospital, Kazan) for providing clinical characteristics of the SLE patients.
The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.
Compliance with Ethical Standards
The study was approved by the Ethical Committee of Kazan State Medical Academy (Kazan, Russian Federation) and performed in accordance with the Declaration of Helsinki.
Conflict of Interest
The authors declare that they have no conflict of interest.
- 8.Sellam, J., Proulle, V., Jungel, A., Ittah, M., Miceli Richard, C., Gottenberg, J. E., Toti, F., Benessiano, J., Gay, S., Freyssinet, J. M., & Mariette, X. (2009). Increased levels of circulating microparticles in primary Sjorgren’s syndrome, systemic lupus erythematosus and rheumatoid arthritis and relation with disease activity. Arthritis Research & Therapy, 11, R156.CrossRefGoogle Scholar
- 13.Mobarrez, F., Vikerfors, A., Gustafsson, J. T., Gunnarsson, I., Zickert, A., Larsson, A., Pisetsky, D. S., Wallén, H., & Svenungsson, E. (2016). Microparticles in the blood of patients with systemic lupus erythematosus (SLE): phenotypic characterization and clinical associations. Scientific Reports, 6, 36025.CrossRefGoogle Scholar
- 14.Nielsen, C. T. (2012). Circulating microparticles in systemic lupus erythematosus. Danish Medical Journal, 59, B4548.Google Scholar
- 16.Dieker, J., Tel, J., Pieterse, E., Thielen, A., Rother, N., Bakker, M., Fransen, J., Dijkman, H. B., Berden, J. H., de Vries, J. M., Hilbrands, L. B., & van der Vlag, J. (2016). Circulating apoptotic microparticles in systemic lupus erythematosus patients drive the activation of dendritic cell subsets and prime neutrophils for NETosis. Arthritis & Rhematology, 68, 462–472.CrossRefGoogle Scholar